Science 37
Uses advanced telemedicine technology and patient-centric innovative networked clinical research models to rapidly accelerate biomedical discovery and bring down the costs of clinical trials.
Launch date
Employees
Market cap
€31.5m
Enterprise valuation
(€19m) (Public information from Mar 2024)
Share price
$5.75 SNCE
Morrisville North Carolina (HQ)
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|
Revenues | 23.7m | 59.6m | 70.1m | 58.4m | 62.8m | 75.2m |
% growth | - | 151 % | 18 % | (17 %) | 8 % | 20 % |
EBITDA | (26.5m) | (24.6m) | (139m) | (32.4m) | (17.1m) | (2.9m) |
% EBITDA margin | (112 %) | (41 %) | (199 %) | (55 %) | (27 %) | (4 %) |
Profit | (31.7m) | (94.3m) | (51.0m) | (72.8m) | (38.4m) | (24.9m) |
% profit margin | (134 %) | (158 %) | (73 %) | (125 %) | (61 %) | (33 %) |
EV / revenue | - | 20.4x | -0.8x | -0.3x | 0.3x | 0.6x |
EV / EBITDA | - | -49.4x | 0.4x | 0.5x | -1.1x | -15.8x |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$6.5m | Series A | ||
$31.0m | Series B | ||
$29.0m | Series C | ||
$31.0m | Series B | ||
$35.0m | Series D | ||
$40.0m | Late VC | ||
$75.0m Valuation: $1.1b 44.3x EV/LTM Revenues -39.7x EV/LTM EBITDA | SPAC IPO | ||
$200m Valuation: $1.1b 44.3x EV/LTM Revenues -39.7x EV/LTM EBITDA | SPAC Private Placement | ||
* | $38.0m Valuation: $38.0m | Acquisition | |
Total Funding | €339m |
Related Content
Recent News about Science 37
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Science 37
EditACQUISITION by Science 37 Feb 2023